AIDS Vaccine Week articles from February 2009

AIDS Vaccine Week archives from February 2009

New HIV/AIDS study findings reported from University of Lausanne.
February 2, 2009... "The STEP HIV vaccine trial, which evaluated a replication-defective adenovirus type 5 (Ad5) vector vaccine, was recently stopped. The reasons for this included lack of efficacy of the vaccine and a twofold increase in the incidence of HIV...

Research from University of New South Wales provides new data about HIV/AIDS co-infection.
February 2, 2009... In this recent study, researchers in Sydney, Australia conducted a study "To evaluate the immune status and vaccination needs of first-year medical students in relation to bloodborne viruses and common vaccine-preventable diseases. setting and...

Studies from A. Jain and colleagues provide new data on tuberculosis.
February 2, 2009... "Drug resistant tuberculosis is a man made problem. While tuberculosis is hundred percent curable, multidrug resistant tuberculosis (MDR-TB) is difficult to treat," researchers in Lucknow, India report (see also Tuberculosis). "Inadequate...

NexBio Completes First-in-Man Clinical Trial With DAS181 (Fludase(R)) and Strengthens Clinical Leadership.
February 2, 2009... NexBio announces the completion of its First-In-Man clinical trial of DAS181 (Fludase(R)), an investigational drug candidate for influenza. The single-dose, escalating Phase I study completed in December 2008 was designed to assess DAS181...

Research reports from University of Cape Town provide new insights into cancer vaccines.(Report)
February 9, 2009... "This article reports on qualitative research investigating key challenges and barriers towards human papillomavirus (HPV) vaccine introduction in the Western Cape Province, South Africa. A total of 50 in-depth interviews and 6 focus groups...

Study results from Y.X. Xu and colleagues in the area of cancer vaccines published.
February 9, 2009... According to a study from the United States, "HLA-A2 tetramer flow cytometry, IFN gamma real time RT-PCR and IFN gamma ELISPOT assays are commonly used as surrogate immunological endpoints for cancer immunotherapy. While these are often used as...

New HIV/AIDS study findings reported from B. Silbermann and co-authors.
February 9, 2009... "Long-term persistence of HIV vaccine-induced seropositivity in uninfected HIV vaccine recipients remains unknown," scientists in Paris, France report (see also HIV/AIDS). "The duration of HIV humoral-induced responses was assessed in 72...

Scientists at Florida State University publish research in HIV/AIDS.
February 9, 2009... "A detailed understanding of the morphology of the HIV-1 envelope (Env) spike is key to understanding viral pathogenesis and for informed vaccine design. We have previously presented a cryoelectron microscopic tomogram (cryoET) of the Env...

Studies from E.C. Speelmon et al add new findings in the area of HIV/AIDS.
February 9, 2009... "Rare individuals report repeated unprotected HIV-1 sexual exposures, yet remain seronegative for years. We investigated the possibility that reduced in vitro CD4(+) T cell susceptibility to HIV-1 infection protects such highly exposed...

Studies conducted at M. Cruciani et al on immunization recently published.(Report)
February 9, 2009... "Sixty-five HIV-infected patients received high-dose (40 mu g). short interval HBV vaccine. In non-responders to the initial immunization, 1-3 boosters were administered," investigators in Verona, Italy report (see also Immunization). ...

Data from Emory Vaccine Center provide new insights into HIV/AIDS.
February 16, 2009... According to a study from the United States, "The HIV/AIDS epidemic has profoundly impacted South Africa's healthcare system, greatly hampering its ability to scale-up the provision of antiretroviral therapy (ART). While one way to provide...

New findings in HIV/AIDS described by A. Upadhyay and co-researchers.
February 16, 2009... According to a study from the United States, "Anti-human immunodeficiency virus-1 (HIV-1) polyamide (peptide) nucleic acids (PNAs) conjugated with cell-penetrating peptides (CPPs) targeted to the viral genome are potent virucidal and antiviral...

Researchers from New York University, Medical Department report details of new studies and findings in the area of HIV/AIDS.
February 16, 2009... Researchers in the United States conducted a study "To determine the frequency of dual inter- and intra-subtype HIV-1 infection among a cohort of 64 longitudinally-studied, HIV-1-positive individuals in Yaounde, Cameroon. Blood was collected...

Studies from P. Suntharasamai and colleagues reveal new findings on HIV/AIDS.(Clinical report)
February 16, 2009... "To determine if incarceration was associated with human immunodeficiency virus (HIV) infection and identify risk factors for incarceration among injection drug users (IDUs) participating in an HIV vaccine trial in Bangkok. The AIDSVAX B/E HIV...

Research on HIV/AIDS co-infection detailed by scientists at University of Cape Town.
February 16, 2009... According to a study from Cape Town, South Africa, "The extent to which human immunodeficiency virus (HIV-1) infection impacts on the ability to mount an effective immune response to HPV is unknown, but is relevant in planning HPV vaccine...

Diagnostic HYBRIDS and Case Western Reserve University Announce Licensing Agreement for the Development of an HIV Tropism and Drug Resistance Platform.(Company overview)
February 16, 2009... Diagnostic HYBRIDS and Case Western Reserve University have signed an exclusive worldwide licensing agreement granting Diagnostic HYBRIDS rights to a novel yeast-based virus cloning technology invented by noted Human Immunodeficiency Virus...

Omnia Biologics and Sumagen Announce Successful Manufacture of HIV/AIDS Vaccine Phase I Material.
February 16, 2009... Omnia Biologics, Inc. (Rockville, MD) and Sumagen Co., Ltd. (London, ON) today jointly announced the successful completion of cGMP manufacture of SumagenEs HIV/AIDS vaccine for a Phase I clinical trial. Safe, effective vaccines for HIV...

Rotary Members Worldwide Prepare for Mass Immunization Campaigns In Polio-Endemic Countries.
February 16, 2009... In the coming months, hundreds of Rotary club members from the United States, Canada, Australia, Denmark, Italy, Korea, the United Kingdom and the Caribbean will join thousands of their fellow Rotary members, other volunteers and health workers...

Standard & Poor's Initiates Factual Stock Report Coverage on GeoVax Labs, Inc.
February 16, 2009... Standard & PoorEs announced that it has commenced Factual Stock Report coverage on GeoVax Labs, Inc (see also Standard & PoorEs). GeoVax Labs, Inc. (BB:GOVX), is a biotechnology company developing human vaccines for diseases caused by HIV-1...

New findings from MS Center describe advances in HIV/AIDS.
February 23, 2009... According to a study from Manguinhos, Brazil, "Rhesus monkeys are relevant models for human diseases. The simian immunodeficiency virus (SIV) infection is an useful macaque model for assessing human immunodeficiency virus (HIV) vaccine...

New HIV/AIDS study findings recently were published by R.G. Ptak and co-researchers.
February 23, 2009... According to recent research from the United States, "Although many interactions between HIV-1 and human proteins have been reported in the scientific literature, no publicly accessible source for efficiently reviewing this information was...

Research from I. Lindh and colleagues has provided new data on HIV/AIDS.
February 23, 2009... According to recent research from Solna, Sweden, "Development of transgenic edible plants, to be used as production, storage and delivery systems for recombinant vaccine antigens, is a promising strategy to obtain cost effective vaccines...

Research results from W. Fu and co-authors update knowledge of HIV/AIDS.
February 23, 2009... According to recent research from the United States, "The 'Human Immunodeficiency Virus Type 1 (HIV-1), Human Protein Interaction Database', available through the National Library of Medicine at www.ncbi.nlm.nih.gov/RefSeq/HIVInteractions, was...

Studies from S. Limou et al add new findings in the area of HIV/AIDS.
February 23, 2009... "To elucidate the genetic factors predisposing to AIDS progression, we analyzed a unique cohort of 275 human immunodeficiency virus (HIV) type 1-seropositive nonprogressor patients in relation to a control group of 1352 seronegative individuals...

Study data from New York University provide new insights into HIV/AIDS.
February 23, 2009... According to a study from the United States, "To design a vaccine that will remain potent against HIV-1, the immunogenic regions in the viral envelope that tend to change as well as those that remain constant over time must be identified. To...

Study findings on adenovirus are outlined in reports from Yokohama City University, Department of Molecular.(Report)
February 23, 2009... New investigation results, 'Effect of therapeutic immunization using Ad5/35 and MVA vectors on SIV infection of rhesus monkeys undergoing antiretroviral therapy,' are detailed in a study published in Gene Therapy. According to a study from...

Research on bone research detailed by scientists at Institute of Molecular Biology and Pathology.
February 23, 2009... Data detailed in 'T-lymphocyte interaction with stromal, bone and hematopoietic cells in the bone marrow' have been presented. "Mature T cells in the bone marrow (BM) are in constant exchange with the blood pool. Within the BM, T-cell...

Studies from N. Lomax and co-researchers yield new data on HIV/AIDS.
February 23, 2009... Fresh data on HIV/AIDS are presented in the report 'A national review of assessment and monitoring of HIV-infected patients.' According to recent research from Bristol, the United Kingdom, "The British HIV Association (BHIVA) audit subcommittee...

Researchers from University of Pennsylvania publish new studies and findings in the area of HIV/AIDS vaccines.
February 23, 2009... New investigation results, 'AIDS pathogenesis: a tale of two monkeys,' are detailed in a study published in Journal of Medical Primatology. According to a study from the United States, "Despite many years of intense scientific effort, the...

Studies from University of Melbourne provide new data on vaccines.(Report)
February 23, 2009... Research findings, 'Protection afforded by live attenuated SIV is associated with rapid killing kinetics of CTLs,' are discussed in a new report. "Live attenuated SIV vaccines are highly efficacious, but how they mediate protection is poorly...

ImQuest Presents IND-Enabling Safety Pharmacology and Pharmacokinetic Data for the Therapeutic HIV Compound IQP-0410 at Conference on Retroviruses and Opportunistic Infections.(Conference news)
February 23, 2009... ImQuest Life Sciences today presented important new results on the continued development of their small molecule inhibitor of HIV-1 at the 16th CROI meeting held this week in Montreal. The presentation highlighted the advanced development of...